Stay informed
News and Events
See the latest announcements about how Haystack is improving cancer treatment decision-making with better MRD testing.
Recent Updates
News

Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
SOURCE Quest Diagnostics Goal to improve patient outcomes through early, accurate detection of residual or

Precision Medicine World Conference 2023 Silicon Valley
Haystack’s co-founder and Chief Innovation Officer, Josh Cohen, will be participating in a panel discussion

Haystack Oncology Appoints Joel Kaufman as Chief Financial Officer
BALTIMORE, MD, December 1, 2022 – Haystack Oncology (“Haystack”), an oncology company that applies the next

Haystack Oncology Launches with $56 Million in Series A Financing to Accelerate Adoption of Post-Op Cancer Detection Technology and Optimize Cancer Therapy Monitoring and Treatment
Liquid biopsy approach delivers unparalleled sensitivity and specificity for detection of low-frequency mutant molecules to

Applying precision technology to improve the detection of residual disease in cancer patients
Though early cancer diagnosis provides better outcomes for patients, many experience later disease recurrence following

Webinar: Clinicians’ Perspectives on Circulating Tumor DNA MRD Testing in Personalizing Adjuvant Therapy for Stage II Colon Cancer
Our webinar featured on Precision Oncology News on September 22, 2022 is now available on
Events
-
2023 ASCO Annual Meeting
3 weeks ago Conferences and Events -
ISMRC 2023
2 months ago Conferences and Events -
AACR 2023 Annual Meeting
3 months ago Conferences and Events -
2022 ASCO GI Annual Meeting
5 months ago Conferences and Events -
AMP 2022 Annual Meeting
9 months ago Conferences and Events